| Literature DB >> 30076424 |
Savine C S Minderhoud1, Femke van der Stelt2, Mirella M C Molenschot2, Michel S Koster3, Gregor J Krings2, Johannes M P J Breur2.
Abstract
Previously, median effective dose (ED) of 1.6 mSv per three-dimensional rotational angiography (3DRA) has been reported. This study evaluated ED and image quality in 3DRA after implementation of a simple dose reduction protocol in pediatric catheterizations. Simple conversion factors between 3DRA ED and readily available parameters at the cathlab were determined. The dose reduction protocol consisted of frame reduction (60-30 frames/s (f/s)), active collimation of the X-ray beam, usage of a readily available low dosage program, and a pre-3DRA run check. EDs were calculated with Monte Carlo PCXMC 2.0. Three observers blindly assessed 3DRA image quality of the dose reduction and normal-dose cohort. Between October 2014 and October 2015, 84 patients (median age 4.3 years) underwent 100 3DRAs with a median ED of 0.54 mSv (0.12-2.2) using the dose reduction protocol. Median ED in the normal-dose cohort (17 3DRAs) was 1.6 mSv (1.2-4.9). Image quality in the dose reduction cohort remained excellent. Correlations between ED and dose area product (DAP) and ED and skin dose were found with a ρ of 0.82 and 0.83, respectively. ED exposure of the entire catheterization was reduced to 2.64 mSv. Introduction of a simple protocol led to 66% dose reduction in 3DRA and 79% in the entire catheterization. 3DRA image quality in this group remained excellent. In 3DRA ED correlates well with DAP and skin dose, parameters readily available at the cathlab.Entities:
Keywords: Catheterization; Effective dose; Radiation dose reduction; Rotational angiography
Mesh:
Year: 2018 PMID: 30076424 PMCID: PMC6244991 DOI: 10.1007/s00246-018-1943-3
Source DB: PubMed Journal: Pediatr Cardiol ISSN: 0172-0643 Impact factor: 1.655
Baseline characteristics
| Low dose | Normal dose [ | |
|---|---|---|
| Demographic patient data | ||
| Number of patients | 84 | 14 |
| Male, | 39 (46) | 7 (50) |
| Age (years) | 4.29 (0.0–18.8) | 3.79 (0–16.6) |
| Height (cm) | 103.0 (50–176) | 101.5 (50–184) |
| Weight (kg) | 16.15 (2.4–89) | 14.5 (3.4–57.5) |
| BSA (m2) | 0.69 (0.19–2.10) | 0.65 (0.23–1.68) |
| Patient diagnosis | ||
| PA + VSD/TOF, | 23 (27.4) | 4 (28.6) |
| Aortic pathology, | 20 (23.8) | 3 (21.4) |
| Univentricular heart, | 19 (22.6) | 2 (14.3) |
| TGA, | 6 (7.1) | 2 (14.3) |
| Genetic syndrome, | 8 (9.5) | 0 (0) |
| Others, | 8 (9.5) | 3 (21.4) |
| Procedural data | ||
| Number of 3DRAs | 100 | 17 |
| Interventional procedures, | 75 (75) | 12 (71) |
Continuous variables are summarized as median and range, and categorical variables are reported as number of cases (n) and percentage
BSA body surface area, PA pulmonary atresia, TGA transposition of the great arteries, TOF tetralogy of fallot, VSD ventricular septal defect
Technical characteristics
| Low dose | Normal dose [ |
| |
|---|---|---|---|
| Exposure parameters | |||
| Tube voltage 3DRA (kV) | 70 (60–96) | 90 (90–90) | < 0.001 |
| Tube current 3DRA (mA) | 228 (53–395) | 69 (26–363) | < 0.001 |
| Exposure time 3DRA (ms) | 465.5 (333.2–1330) | 843.2 (452.2–868) | < 0.001 |
| Skin dose 3DRA (mGy) | 9 (1.7–83) | 20,86 (10,33–90,69) | < 0.001 |
| DAP 3DRA (mGy·cm2) | 1279 (150–16,987) | 3128 (1231–17,273) | < 0.001 |
| Procedural time (min) | 153 (30–360) | 165 (60–540) | 0.360 |
| Total fluoroscopy time (min) | 28 (0.4–121) | 22 (6.4–81.4) | 0.497 |
| Effective dose | |||
| 3DRA (mSv) | 0.54 (0.12–2.23) | 1.62 (0.70–4.94) | < 0.001 |
| Fluoroscopy (mSv) | 1.53 (0.00–25.40) | 4.4 (0.2–15.8) | 0.002 |
| Angiography (mSv) | 0.45 (0.00–19.33) | 3.6 (0–79.1) | 0.009 |
| Total catheterization (mSv) | 2.64 (0.27–28.13) | 12.4 (2–99.9) | < 0.001 |
| Interventional group | 3.65 (0.49–28.13) | ||
| Diagnostic group | 0.86 (0.27–10.09) | ||
Values represent median and range
Fig. 1Distribution of 3DRA EDs; + indicates mean value. Normal dose: n = 17; low dose: n = 100
Fig. 2a Scatterplot of DAP and ED for patients that underwent a 3DRA in the low-dose cohort—the straight lines indicate the least squared fit for the low-dose cohort. b Scatterplot of skin dose and ED for patients that underwent a 3DRA in the low-dose cohort—the straight lines indicate the least squared fit for the low-dose cohort
Fig. 33DRA with an ED of 0.12 mSv—acquired in a 3-month-old female patient with hypoplastic left heart syndrome and aortic coarctation. The overall image quality was sufficient. a Anterior view; b lateral view; c–e posterior views, clearly showing the aortic coarctation
Comparison of studies on ED in 3DRA
| Author | Year of publication | Patients | Number of patients | Measure of center | ED (mSv) |
|---|---|---|---|---|---|
| Eloot [ | 2013 | Adults | 40 | Median | 5.7 |
| Wielandts [ | 2010 | Adults | 42 | Mean | 6.6 |
| De Buck [ | 2013 | Adults | 40 (75% left atrium) | N/A | 2.6 (left atrium group) |
| Haddad [ | 2016 | Pediatric patient; age unknown | 1 | - | 1.8 |
| Surendran [ | 2017 | ≤ 2 years | 15 | Median | 1.35 |
N/A not available